Novagali Pharma Successfully Enrolls First Patient in U.S. Phase I Clinical Study with CORTIJECT(R) for Diabetic Macular Edema
Novagali Pharma is an ophthalmic pharmaceutical company based in theGenopole biocluster in Evry (France) that develops and commercializesinnovative products. Thanks to its proprietary technology platformsNovasorb(R) and Eyeject(R) the company has developed a broad pipeline of 7innovative products addressing main ocular conditions as well as orphandiseases. Most advanced products include Veka
Date:4/24/2008
Novagali Pharma is an ophthalmic pharmaceutical company based in the
Genopole biocluster in Evry (France) that develops and commercializes
innovative products. Thanks to its proprietary technology platforms
Novasorb(R) and Eyeject(R), the company has developed a broad pipeline of 7
innovative products addressing main ocular conditions as well as orphan
diseases. Most advanced products include Vekacia(R), an orphan product for
treatment of vernal keratoconjunctivitis, Cyclokat(R), a product for the
treatment of moderate-to-severe dry eye syndrome and Cortiject(R) for the
treatment of diabetic retinopathies. Cationorm(R), indicated for dry eye
symptoms is commercialized in France since April 2008. Founded in 2000,
Novagali Pharma has 50 employees.
'/>"/>SOURCE Novagali Pharma Copyright©2008 PR Newswire. All rights reserved | |
Page: 1 2 Related medicine technology :1.
Thomson Scientific Publishes The Ones to Watch - A Quarterly Review of Phase Changes in the Pharmaceutical Pipeline2.
Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)3.
Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML4.
Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia5.
Clinical Trial Effectiveness: How Pharmas & Biotechs Save Cost with Savvy Investigator Management6.
DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,9477.
Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients8.
WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO9.
Par Pharmaceutical Begins Shipment of Additional Dosage Strength of Generic TOPROL-XL(R)10.
Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)11.
Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India